Corisma
CoRISMA MCS Systems Inc. is a medical device company developing a fully implanted mechanical circulation system for patients suffering from advanced heart failure. Spun out of Yale University, the company aims to disrupt the market with its wirelessly powered transcatheter device, seeking to provide alternatives to existing treatments and reduce the economic burden of heart failure.
Industries
Nr. of Employees
small (1-50)
Products
Catheter-delivered fully implanted mechanical circulatory support system (investigational)
A transcatheter-delivered, fully implanted mechanical circulatory support system intended to provide circulatory assistance for patients with advanced heart failure; device is investigational and not CE marked or FDA approved.
Catheter-delivered fully implanted mechanical circulatory support system (investigational)
A transcatheter-delivered, fully implanted mechanical circulatory support system intended to provide circulatory assistance for patients with advanced heart failure; device is investigational and not CE marked or FDA approved.
Services
End-to-end development activities for an investigational, fully implanted circulatory support system, including device engineering, integration of wireless power, and preclinical development.
End-to-end development activities for an investigational, fully implanted circulatory support system, including device engineering, integration of wireless power, and preclinical development.
Expertise Areas
- Mechanical circulatory support
- Transcatheter implantable device engineering
- Implantable pump design
- Wireless power transmission for implants
Key Technologies
- Helicoid pump architecture
- Transcatheter delivery systems
- Wireless energy transfer for implants
- Implantable mechanical circulatory support systems
News & Updates
CoRISMA was selected to present at MedInvest.
The CoRISMA Helicoid Pump was featured in ASAIO Journal.
CoRISMA was awarded a $550,000 NIH grant to accelerate development of its heart failure treatment device.
CoRISMA secured $27 million in funding to advance heart failure treatment technology.
CoRISMA was selected to present at MedInvest.
The CoRISMA Helicoid Pump was featured in ASAIO Journal.
CoRISMA was awarded a $550,000 NIH grant to accelerate development of its heart failure treatment device.
CoRISMA secured $27 million in funding to advance heart failure treatment technology.